@article{88992e7d9273419cb14354e559fe7875,
title = "Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-na{\"i}ve and CYP17 Inhibitor-na{\"i}ve Patients: Follow-up from the ARADES and ARAFOR Trials",
keywords = "darolutamide, oxygenase inhibitor, prostate specific antigen, abdominal pain, adult, aged, antineoplastic activity, arthralgia, Article, backache, bone pain, cancer growth, castration resistant prostate cancer, clinical article, constipation, decreased appetite, dermatitis, diarrhea, dizziness, drug safety, drug tolerability, dysgeusia, dysuria, fatigue, femoral neck fracture, follow up, gynecomastia, headache, hematuria, hot flush, human, hypertension, hyponatremia, influenza, limb pain, lung adenocarcinoma, male, metastasis, nausea, neuroendocrine carcinoma, phase 1 clinical trial, phase 2 clinical trial, rash, respiratory failure, rhinopharyngitis, rhinorrhea, side effect, somnolence, tinnitus, urine incontinence, vomiting, 3122 Cancers",
author = "Shore, {Neal D.} and Tammela, {Teuvo L.} and Christophe Massard and P. Bono and John Aspegren and Mika Mustonen and Karim Fizazi",
year = "2018",
doi = "10.1016/j.euf.2017.01.015",
language = "English",
volume = "4",
pages = "547--553",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier Science B.V.",
number = "4",
}